Pfizer stock at EUR 26.36, up 1.31% in premarket
Published on 11/16/2026 at 08:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPfizer pipeline gains funding support
- Blackstone will fund up to 1.5 billion US dollars of berobenatide development costs through 2028.
- Pfizer retains operational control of the obesity program and plans more than 20 obesity-related trials in 2026.
- The program includes 10 ongoing and planned Phase 3 trials for the investigational monthly GLP-1 treatment.
Pfizer stock traded at 26.36 euros on Lang & Schwarz at 08:29 CET on Monday, November 16, 2026, 1.31 percent above the Xetra close of Friday, November 13, 2026.
Pfizer develops and manufactures medicines and vaccines across areas including oncology, vaccines, inflammation and immunology, rare diseases and hospital care.
Blackstone supports obesity development
On November 11, Pfizer announced a strategic funding agreement with Blackstone Life Sciences for berobenatide, an investigational monthly GLP-1 receptor agonist for chronic weight management and obesity-related conditions. Funds managed by Blackstone will cover up to 1.5 billion US dollars of development costs through 2028, according to the Pfizer press release.
Blackstone is eligible for milestone-based payments tied to US regulatory approval of monthly injectable monotherapy and commercial sales milestones. Pfizer said it retains full operational control and decision-making for the program. The company plans to advance more than 20 trials for obesity and related conditions in 2026, including 10 ongoing and planned Phase 3 trials for berobenatide.
For broader market context, follow the S&P 500.
